Jump to main content
Takeda, in alignment with the U.S. Food and Drug Administration (FDA), will close the U.S. Special Use Program (SUP) for NATPARA® (parathyroid hormone) for Injection at the end of 2025. TAKEDA WILL CEASE SHIPMENTS OF NATPARA BY DECEMBER 31, 2025 AND NATPARA WILL NO LONGER BE AVAILABLE TO SUP PATIENTS. Learn How This May Affect You
NATPARA logo.

NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

See full indication

See less indication

NATPARA® is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.

See full indication

See less indication

NATPARA logo.

Understanding Hypoparathyroidism

Hypoparathyroidism interferes with calcium homeostasis2

Hypoparathyroidism is a complex endocrine disorder characterized by absent or inappropriately low levels of parathyroid hormone (PTH). Compromised endogenous PTH function can lead to hypocalcemia.2-4

Calcium levels can be maintained through interactions that involve endogenous PTH and the bones, kidneys, intestines, and the active form of vitamin D2

Graph of normal PTH function.

Insufficient endogenous PTH can interfere with certain processes of these organs which can lead to2,3:

  • Decreased intestinal calcium absorption due to a decrease in the conversion of vitamin D to its active form
  • Decreased renal reabsorption of calcium
  • Decreased bone turnover
Graph of compromised PTH function.

References: 1. NATPARA [package insert]. Shire Pharmaceuticals, Inc. 2. Shoback D. N Engl J Med. 2008;359(4):391-403. 3. Bilezikian JP, Khan A, Potts JT Jr, et al. J Bone Miner Res. 2011;26(10):2317-2337. 4. Fong J, Khan A. Can Fam Physician. 2012;58(2):158-162.

NATPARA® and the NATPARA Logo® are registered trademarks of Takeda Pharmaceuticals, U.S.A,. Inc.

Takeda logo.

©2025 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited.
US-NAT-0590v1.0 01/25

All content in this site, including text, images, graphics, sound files, and their arrangement, is copyrighted and owned by Takeda and is protected by international copyright laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution, nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our Legal Notice for more information. While Takeda Pharmaceutical Company Limited makes reasonable efforts to include accurate, up-to-date information on this site, Takeda Pharmaceutical Company Limited makes no warranties or representations as to its accuracy. Takeda Pharmaceutical Company Limited assumes no liability for any errors or omissions in the content of this site.